{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:06:01Z","timestamp":1793729161744,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T00:00:00Z","timestamp":1426464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/nm.3827","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T11:01:31Z","timestamp":1426503691000},"page":"318-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":268,"title":["Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome"],"prefix":"10.1038","volume":"21","author":[{"given":"Gabriele","family":"Deidda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Parrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shovan","family":"Naskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio F","family":"Bozarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Contestabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cancedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,16]]},"reference":[{"key":"BFnm3827_CR1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nrn3314","volume":"13","author":"M Dierssen","year":"2012","unstructured":"Dierssen, M. Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci. 13, 844\u2013858 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnm3827_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ng1095-177","volume":"11","author":"RH Reeves","year":"1995","unstructured":"Reeves, R.H. et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11, 177\u2013184 (1995).","journal-title":"Nat. Genet."},{"key":"BFnm3827_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neulet.2005.03.031","volume":"382","author":"AC Costa","year":"2005","unstructured":"Costa, A.C. & Grybko, M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 382, 317\u2013322 (2005).","journal-title":"Neurosci. Lett."},{"key":"BFnm3827_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nn1860","volume":"10","author":"F Fernandez","year":"2007","unstructured":"Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411\u2013413 (2007).","journal-title":"Nat. Neurosci."},{"key":"BFnm3827_CR5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/sj.npp.1301535","volume":"33","author":"AC Costa","year":"2008","unstructured":"Costa, A.C., Scott-McKean, J.J. & Stasko, M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33, 1624\u20131632 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"BFnm3827_CR6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nn.2600","volume":"13","author":"L Chakrabarti","year":"2010","unstructured":"Chakrabarti, L. et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 13, 927\u2013934 (2010).","journal-title":"Nat. Neurosci."},{"key":"BFnm3827_CR7","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1523\/JNEUROSCI.1766-04.2004","volume":"24","author":"AM Kleschevnikov","year":"2004","unstructured":"Kleschevnikov, A.M. et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153\u20138160 (2004).","journal-title":"J. Neurosci."},{"key":"BFnm3827_CR8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.nbd.2011.10.009","volume":"45","author":"AM Kleschevnikov","year":"2012","unstructured":"Kleschevnikov, A.M. et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 45, 683\u2013691 (2012).","journal-title":"Neurobiol. Dis."},{"key":"BFnm3827_CR9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40263-013-0089-3","volume":"27","author":"AC Costa","year":"2013","unstructured":"Costa, A.C. & Scott-McKean, J.J. Prospects for improving brain function in individuals with Down syndrome. CNS Drugs 27, 679\u2013702 (2013).","journal-title":"CNS Drugs"},{"key":"BFnm3827_CR10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881111405366","volume":"25","author":"J Braudeau","year":"2011","unstructured":"Braudeau, J. et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 25, 1030\u20131042 (2011).","journal-title":"J. Psychopharmacol."},{"key":"BFnm3827_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-6606-6-33","volume":"6","author":"M Szemes","year":"2013","unstructured":"Szemes, M., Davies, R.L., Garden, C.L. & Usowicz, M.M. Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome. Mol. Brain 6, 33 (2013).","journal-title":"Mol. Brain"},{"key":"BFnm3827_CR12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.expneurol.2011.11.033","volume":"233","author":"TK Best","year":"2012","unstructured":"Best, T.K., Cramer, N.P., Chakrabarti, L., Haydar, T.F. & Galdzicki, Z. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp. Neurol. 233, 749\u2013757 (2012).","journal-title":"Exp. Neurol."},{"key":"BFnm3827_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2011.12.034","volume":"1440","author":"A Mitra","year":"2012","unstructured":"Mitra, A., Blank, M. & Madison, D.V. Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome. Brain Res. 1440, 1\u20138 (2012).","journal-title":"Brain Res."},{"key":"BFnm3827_CR14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/jphysiol.2006.114868","volume":"579","author":"JE Hanson","year":"2007","unstructured":"Hanson, J.E., Blank, M., Valenzuela, R.A., Garner, C.C. & Madison, D.V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J. Physiol. (Lond.) 579, 53\u201367 (2007).","journal-title":"J. Physiol. (Lond.)"},{"key":"BFnm3827_CR15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cne.20844","volume":"494","author":"C Harashima","year":"2006","unstructured":"Harashima, C. et al. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. J. Comp. Neurol. 494, 815\u2013833 (2006).","journal-title":"J. Comp. Neurol."},{"key":"BFnm3827_CR16","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1523\/JNEUROSCI.5169-06.2007","volume":"27","author":"L Cancedda","year":"2007","unstructured":"Cancedda, L., Fiumelli, H., Chen, K. & Poo, M.M. Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J. Neurosci. 27, 5224\u20135235 (2007).","journal-title":"J. Neurosci."},{"key":"BFnm3827_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fncel.2014.00119","volume":"8","author":"G Deidda","year":"2014","unstructured":"Deidda, G., Bozarth, I.F. & Cancedda, L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front. Cell. Neurosci. 8, 119 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"BFnm3827_CR18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/adc.52.11.877","volume":"52","author":"OC Ward","year":"1977","unstructured":"Ward, O.C. & Lam, L.K. Bumetanide in heart failure in infancy. Arch. Dis. Child. 52, 877\u2013882 (1977).","journal-title":"Arch. Dis. Child."},{"key":"BFnm3827_CR19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1528-1167.2011.03203.x","volume":"52","author":"EH Maa","year":"2011","unstructured":"Maa, E.H., Kahle, K.T., Walcott, B.P., Spitz, M.C. & Staley, K.J. Diuretics and epilepsy: will the past and present meet? Epilepsia 52, 1559\u20131569 (2011).","journal-title":"Epilepsia"},{"key":"BFnm3827_CR20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuron.2005.10.025","volume":"48","author":"H Fiumelli","year":"2005","unstructured":"Fiumelli, H., Cancedda, L. & Poo, M.M. Modulation of GABAergic transmission by activity via postsynaptic Ca2+-dependent regulation of KCC2 function. Neuron 48, 773\u2013786 (2005).","journal-title":"Neuron"},{"key":"BFnm3827_CR21","doi-asserted-by":"crossref","first-page":"e1002149","DOI":"10.1371\/journal.pcbi.1002149","volume":"7","author":"N Doyon","year":"2011","unstructured":"Doyon, N. et al. Efficacy of synaptic inhibition depends on multiple, dynamically interacting mechanisms implicated in chloride homeostasis. PLoS Comput. Biol. 7, e1002149 (2011).","journal-title":"PLoS Comput. Biol."},{"key":"BFnm3827_CR22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ncomms1744","volume":"3","author":"F Succol","year":"2012","unstructured":"Succol, F., Fiumelli, H., Benfenati, F., Cancedda, L. & Barberis, A. Intracellular chloride concentration influences the GABAA receptor subunit composition. Nat. Commun. 3, 738 (2012).","journal-title":"Nat. Commun."},{"key":"BFnm3827_CR23","first-page":"613","volume":"117","author":"RA Rissman","year":"2011","unstructured":"Rissman, R.A. & Mobley, W.C. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J. Neurochem. 117, 613\u2013622 (2011).","journal-title":"J. Neurochem."},{"key":"BFnm3827_CR24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/archneur.1991.00530150088024","volume":"48","author":"SM Pueschel","year":"1991","unstructured":"Pueschel, S.M., Louis, S. & McKnight, P. Seizure disorders in Down syndrome. Arch. Neurol. 48, 318\u2013320 (1991).","journal-title":"Arch. Neurol."},{"key":"BFnm3827_CR25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3233\/JAD-2010-100087","volume":"20","author":"CJ Westmark","year":"2010","unstructured":"Westmark, C.J., Westmark, P.R. & Malter, J.S. Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. J. Alzheimers Dis. 20, 1009\u20131013 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnm3827_CR26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hipo.20225","volume":"16","author":"L Danglot","year":"2006","unstructured":"Danglot, L., Triller, A. & Marty, S. The development of hippocampal interneurons in rodents. Hippocampus 16, 1032\u20131060 (2006).","journal-title":"Hippocampus"},{"key":"BFnm3827_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.1991.tb25929.x","volume":"627","author":"BE Alger","year":"1991","unstructured":"Alger, B.E. Gating of GABAergic inhibition in hippocampal pyramidal cells. Ann. NY Acad. Sci. 627, 249\u2013263 (1991).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnm3827_CR28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2012.05.027","volume":"1465","author":"MM Usowicz","year":"2012","unstructured":"Usowicz, M.M. & Garden, C.L. Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome. Brain Res. 1465, 10\u201317 (2012).","journal-title":"Brain Res."},{"key":"BFnm3827_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fncir.2013.00205","volume":"7","author":"AI Wlodarczyk","year":"2013","unstructured":"Wlodarczyk, A.I. et al. Tonic GABAA conductance decreases membrane time constant and increases EPSP-spike precision in hippocampal pyramidal neurons. Front. Neural Circuits 7, 205 (2013).","journal-title":"Front. Neural Circuits"},{"key":"BFnm3827_CR30","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1073\/pnas.0704832104","volume":"104","author":"C Jean-Xavier","year":"2007","unstructured":"Jean-Xavier, C., Mentis, G.Z., O'Donovan, M.J., Cattaert, D. & Vinay, L. Dual personality of GABA\/glycine-mediated depolarizations in immature spinal cord. Proc. Natl. Acad. Sci. USA 104, 11477\u201311482 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3827_CR31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ncomms1377","volume":"2","author":"I Song","year":"2011","unstructured":"Song, I., Savtchenko, L. & Semyanov, A. Tonic excitation or inhibition is set by GABAA conductance in hippocampal interneurons. Nat. Commun. 2, 376 (2011).","journal-title":"Nat. Commun."},{"key":"BFnm3827_CR32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00335-011-9356-0","volume":"22","author":"A Duchon","year":"2011","unstructured":"Duchon, A. et al. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm. Genome 22, 674\u2013684 (2011).","journal-title":"Mamm. Genome"},{"key":"BFnm3827_CR33","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/tp.2012.124","volume":"2","author":"E Lemonnier","year":"2012","unstructured":"Lemonnier, E. et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl. Psychiatry 2, e202 (2012).","journal-title":"Transl. Psychiatry"},{"key":"BFnm3827_CR34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00003495-198428050-00003","volume":"28","author":"A Ward","year":"1984","unstructured":"Ward, A. & Heel, R.C. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 28, 426\u2013464 (1984).","journal-title":"Drugs"},{"key":"BFnm3827_CR35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","volume":"55","author":"M Puskarjov","year":"2014","unstructured":"Puskarjov, M., Kahle, K.T., Ruusuvuori, E. & Kaila, K. Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. Epilepsia 55, 806\u2013818 (2014).","journal-title":"Epilepsia"},{"key":"BFnm3827_CR36","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jchromb.2011.02.018","volume":"879","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. Sensitive isotope dilution liquid chromatography\/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 998\u20131002 (2011).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"BFnm3827_CR37","doi-asserted-by":"crossref","first-page":"e57148","DOI":"10.1371\/journal.pone.0057148","volume":"8","author":"RT Cleary","year":"2013","unstructured":"Cleary, R.T. et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One 8, e57148 (2013).","journal-title":"PLoS One"},{"key":"BFnm3827_CR38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nn.3890","volume":"18","author":"G Deidda","year":"2015","unstructured":"Deidda, G. et al. Early depolarizing GABA controls critical-period plasticity in the rat visual cortex. Nat. Neurosci. 18, 87\u201396 (2015).","journal-title":"Nat. Neurosci."},{"key":"BFnm3827_CR39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/nm1301","volume":"11","author":"VI Dzhala","year":"2005","unstructured":"Dzhala, V.I. et al. NKCC1 transporter facilitates seizures in the developing brain. Nat. Med. 11, 1205\u20131213 (2005).","journal-title":"Nat. Med."},{"key":"BFnm3827_CR40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1113\/jphysiol.2006.107086","volume":"573","author":"ST Sipil\u00e4","year":"2006","unstructured":"Sipil\u00e4, S.T., Schuchmann, S., Voipio, J., Yamada, J. & Kaila, K. The cation-chloride cotransporter NKCC1 promotes sharp waves in the neonatal rat hippocampus. J. Physiol. 573, 765\u2013773 (2006).","journal-title":"J. Physiol."},{"key":"BFnm3827_CR41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0883073809333526","volume":"24","author":"KT Kahle","year":"2009","unstructured":"Kahle, K.T., Barnett, S.M., Sassower, K.C. & Staley, K.J. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J. Child Neurol. 24, 572\u2013576 (2009).","journal-title":"J. Child Neurol."},{"key":"BFnm3827_CR42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1528-1167.2009.02048.x","volume":"50","author":"A Mazarati","year":"2009","unstructured":"Mazarati, A., Shin, D. & Sankar, R. Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia 50, 2117\u20132122 (2009).","journal-title":"Epilepsia"},{"key":"BFnm3827_CR43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/ALN.0b013e3181cf9138","volume":"112","author":"DA Edwards","year":"2010","unstructured":"Edwards, D.A. et al. Bumetanide alleviates epileptogenic and neurotoxic effects of sevoflurane in neonatal rat brain. Anesthesiology 112, 567\u2013575 (2010).","journal-title":"Anesthesiology"},{"key":"BFnm3827_CR44","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","volume":"99","author":"E Lemonnier","year":"2010","unstructured":"Lemonnier, E. & Ben-Ari, Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr. 99, 1885\u20131888 (2010).","journal-title":"Acta Paediatr."},{"key":"BFnm3827_CR45","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/apa.12235","volume":"102","author":"E Lemonnier","year":"2013","unstructured":"Lemonnier, E. et al. Treating Fragile X syndrome with the diuretic bumetanide: a case report. Acta Paediatr. 102, e288\u2013e290 (2013).","journal-title":"Acta Paediatr."},{"key":"BFnm3827_CR46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1247190","volume":"343","author":"R Tyzio","year":"2014","unstructured":"Tyzio, R. et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 343, 675\u2013679 (2014).","journal-title":"Science"},{"key":"BFnm3827_CR47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1362361313514141","volume":"19","author":"N Hadjikhani","year":"2013","unstructured":"Hadjikhani, N. et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism 19, 149\u2013157 (2013).","journal-title":"Autism"},{"key":"BFnm3827_CR48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.33549\/physiolres.931897","volume":"58","author":"P Mares","year":"2009","unstructured":"Mares, P. Age- and dose-specific anticonvulsant action of bumetanide in immature rats. Physiol. Res. 58, 927\u2013930 (2009).","journal-title":"Physiol. Res."},{"key":"BFnm3827_CR49","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","volume":"30","author":"C Brandt","year":"2010","unstructured":"Brandt, C., Nozadze, M., Heuchert, N., Rattka, M. & Loscher, W. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J. Neurosci. 30, 8602\u20138612 (2010).","journal-title":"J. Neurosci."},{"key":"BFnm3827_CR50","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cercor\/bhq124","volume":"21","author":"DD Wang","year":"2011","unstructured":"Wang, D.D. & Kriegstein, A.R. Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. Cereb. Cortex 21, 574\u2013587 (2011).","journal-title":"Cereb. Cortex"},{"key":"BFnm3827_CR51","unstructured":"Validus Pharmaceuticals Bumex: brand of bumetanide tablets. Drugs@FDA: FDA Approved Drug Products http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/018225s024lbl.pdf (2008)."},{"key":"BFnm3827_CR52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.1977.tb00664.x","volume":"4","author":"PJ Pentik\u00e4inen","year":"1977","unstructured":"Pentik\u00e4inen, P.J., Penttil\u00e4, A., Neuvonen, P. & Gothoni, G. Fate of [14C]-bumetanide in man. Br. J. Clin. Pharmacol. 4, 39\u201344 (1977).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnm3827_CR53","first-page":"66","volume":"22","author":"EH Ostergaard","year":"1972","unstructured":"Ostergaard, E.H., Magnussen, M.P., Nielsen, C.K., Eilertsen, E. & Frey, H.H. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung 22, 66\u201372 (1972).","journal-title":"Arzneimittelforschung"},{"key":"BFnm3827_CR54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","volume":"69","author":"W L\u00f6scher","year":"2013","unstructured":"L\u00f6scher, W., Puskarjov, M. & Kaila, K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 69, 62\u201374 (2013).","journal-title":"Neuropharmacology"},{"key":"BFnm3827_CR55","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","volume":"20","author":"SM Strittmatter","year":"2014","unstructured":"Strittmatter, S.M. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat. Med. 20, 590\u2013591 (2014).","journal-title":"Nat. Med."},{"key":"BFnm3827_CR56","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1523\/JNEUROSCI.4447-13.2014","volume":"34","author":"Q He","year":"2014","unstructured":"He, Q., Nomura, T., Xu, J. & Contractor, A. The developmental switch in GABA polarity is delayed in fragile X mice. J. Neurosci. 34, 446\u2013450 (2014).","journal-title":"J. Neurosci."},{"key":"BFnm3827_CR57","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger, D. et al. Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis. Nat. Med. 14, 843\u2013848 (2008).","journal-title":"Nat. Med."},{"key":"BFnm3827_CR58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature11356","volume":"489","author":"S Han","year":"2012","unstructured":"Han, S. et al. Autistic-like behaviour in Scn1a+\/\u2212 mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489, 385\u2013390 (2012).","journal-title":"Nature"},{"key":"BFnm3827_CR59","doi-asserted-by":"crossref","first-page":"14074","DOI":"10.1523\/JNEUROSCI.3287-12.2012","volume":"32","author":"E Castr\u00e9n","year":"2012","unstructured":"Castr\u00e9n, E., Elgersma, Y., Maffei, L. & Hagerman, R. Treatment of neurodevelopmental disorders in adulthood. J. Neurosci. 32, 14074\u201314079 (2012).","journal-title":"J. Neurosci."},{"key":"BFnm3827_CR60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1172\/JCI64650","volume":"123","author":"A Contestabile","year":"2013","unstructured":"Contestabile, A. et al. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 123, 348\u2013361 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnm3827_CR61","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature09965","volume":"472","author":"J Pe\u00e7a","year":"2011","unstructured":"Pe\u00e7a, J. et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437\u2013442 (2011).","journal-title":"Nature"},{"key":"BFnm3827_CR62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0003-2697(89)90652-0","volume":"178","author":"AS Verkman","year":"1989","unstructured":"Verkman, A.S., Sellers, M.C., Chao, A.C., Leung, T. & Ketcham, R. Synthesis and characterization of improved chloride-sensitive fluorescent indicators for biological applications. Anal. Biochem. 178, 355\u2013361 (1989).","journal-title":"Anal. Biochem."},{"key":"BFnm3827_CR63","doi-asserted-by":"crossref","first-page":"e26549","DOI":"10.1371\/journal.pone.0026549","volume":"6","author":"CJ Westmark","year":"2011","unstructured":"Westmark, C.J. et al. Reversal of fragile X phenotypes by manipulation of AbetaPP\/Abeta levels in Fmr1KO mice. PLoS ONE 6, e26549 (2011).","journal-title":"PLoS ONE"},{"key":"BFnm3827_CR64","doi-asserted-by":"crossref","unstructured":"Peterson, S.L. & Albertson, T.E. Neuropharmacology Methods in Epilepsy Research (CRC Press, 1998).","DOI":"10.1201\/9781420048889"},{"key":"BFnm3827_CR65","doi-asserted-by":"crossref","unstructured":"Hallett, P.J., Collins, T.L., Standaert, D.G. & Dunah, A.W. Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr. Protoc. Neurosci. Chapter 1, Unit 1.16 (2008).","DOI":"10.1002\/0471142301.ns0116s42"},{"key":"BFnm3827_CR66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-0270(03)00050-5","volume":"125","author":"J Thomas-Crusells","year":"2003","unstructured":"Thomas-Crusells, J., Vieira, A., Saarma, M. & Rivera, C. A novel method for monitoring surface membrane trafficking on hippocampal acute slice preparation. J. Neurosci. Methods 125, 159\u2013166 (2003).","journal-title":"J. Neurosci. Methods"},{"key":"BFnm3827_CR67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S.A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622 (2009).","journal-title":"Clin. Chem."},{"key":"BFnm3827_CR68","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/emboj.2013.231","volume":"32","author":"D Pozzi","year":"2013","unstructured":"Pozzi, D. et al. REST\/NRSF-mediated intrinsic homeostasis protects neuronal networks from hyperexcitability. EMBO J. 32, 2994\u20133007 (2013).","journal-title":"EMBO J."},{"key":"BFnm3827_CR69","doi-asserted-by":"crossref","first-page":"RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).","journal-title":"Genome Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3827","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:49:46Z","timestamp":1684435786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,16]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFnm3827"],"URL":"https:\/\/doi.org\/10.1038\/nm.3827","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725390463.793506606","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,16]]},"assertion":[{"value":"8 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. and L.C. are named as co-inventors on International Patent Application PCT\/EP2014\/078561, filed on December 18, 2014, claiming priority over US Provisional Application US 61\/919,195, priority date December 20, 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}